Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Consensus Rating of “Buy” by Brokerages

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have received an average recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.30.

CGTX has been the subject of several recent research reports. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. Chardan Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Cognition Therapeutics in a report on Thursday, December 19th. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Finally, HC Wainwright boosted their target price on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th.

Cognition Therapeutics Price Performance

Cognition Therapeutics stock opened at $0.61 on Wednesday. The firm has a 50-day moving average of $0.67 and a 200-day moving average of $0.58. The company has a market cap of $25.39 million, a price-to-earnings ratio of -0.63 and a beta of 0.96. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95.

Institutional Trading of Cognition Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CGTX. SG Americas Securities LLC bought a new position in shares of Cognition Therapeutics during the 4th quarter worth approximately $26,000. Two Sigma Investments LP lifted its holdings in Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after purchasing an additional 42,321 shares during the last quarter. Virtu Financial LLC bought a new position in Cognition Therapeutics during the third quarter worth $27,000. Sigma Planning Corp increased its holdings in shares of Cognition Therapeutics by 14.6% in the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after purchasing an additional 28,705 shares during the period. Institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.